कंपनी का अवलोकन
electroCore, Inc. operates as a bioelectronic technology medicine and general wellness enterprise that specializes in non-invasive vagus nerve stimulation (nVNS) technology platforms across the United States, the United Kingdom, and international markets. The firm focuses on the development of gammaCore, a prescription-only handheld device designed for medical applications. This company functions within the Healthcare sector, specifically the Medical Devices industry, which implies a focus on innovation in therapeutic tools and regulatory compliance. The organization employs 83 individuals and holds a market capitalization of $53.76M, while reporting an annual revenue of $32.03M. These valuation and revenue metrics indicate that electroCore, Inc. maintains a small-cap profile relative to major industry peers, suggesting a nascent stage of market penetration or a specialized niche positioning within the broader medical device landscape. The modest employee count of 83 further underscores a lean operational structure typical of early-to-mid-stage biotechnology and medical technology firms.
वित्तीय स्वास्थ्य
The company reported a revenue of $32.03M for the trailing twelve months, yet it recorded a net income of $-13,966,000 and an EBITDA of $-12,652,000. The substantial gap between the positive revenue of $32.03M and the significant net loss reveals a cost structure where operating expenses, likely driven by research and development or sales commissions, far exceed gross profits. The firm generated a free cash flow of $-2,707,375, which indicates that current operations are burning cash rather than generating liquidity, thereby limiting immediate financial flexibility for unplanned expenditures. Despite the operating loss, the company holds $11.61M in cash against $9.40M in debt, providing a net cash position that offers a buffer against its current liabilities. The debt-to-equity ratio is listed as N/A due to the negative equity situation, but the absolute comparison of cash to debt suggests a conservative balance sheet stance regarding solvency. Liquidity is assessed via a current ratio of 1.38, which indicates that the company possesses 1.38 dollars of current assets for every dollar of current liabilities, suggesting adequate short-term liquidity to meet obligations. However, the return on equity stands at -478.7% and the return on assets is -42.0%, metrics that reveal management has not yet generated positive returns on the capital invested or the asset base utilized.
मूल्यांकन आकलन
ElectroCore, Inc. exhibits a P/E ratio (TTM) of N/A and a forward P/E of -12.09, implying that the market currently discounts the stock based on projected negative earnings rather than historical profitability. The price-to-book ratio is -31.07, which indicates a market valuation significantly below the book value, a scenario common for unprofitable growth companies where investors price in potential future recovery or asset liquidation value. Alternative valuation metrics show a price-to-sales ratio of 1.68 and an EV/EBITDA of -4.07, suggesting that valuations are being driven by revenue multiples rather than earnings power, as the negative EV/EBITDA reflects the company's inability to cover fixed costs from operations. The stock has traded within a 52-week range between a high of $8.64 and a low of $4.16, placing the current trading context within this volatility band where price discovery is heavily influenced by clinical trial outcomes and regulatory approvals. The beta of 0.60 indicates that the stock's price volatility is approximately 40% lower than the broader market, suggesting it may be less sensitive to general market fluctuations but carries specific idiosyncratic risks.
Growth & Income
The company demonstrated a revenue growth of 31.2% year-over-year, while earnings growth is N/A due to the absence of positive earnings in the prior period. The disparity between strong revenue expansion and negative earnings implies that top-line growth is not yet translating to profitability, likely due to high upfront costs associated with device development and market expansion. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available cash flow is retained and reinvested into the business rather than distributed to shareholders. This reinvestment strategy is typical for growth-stage companies seeking to fund ongoing research, development, or commercialization efforts to achieve future profitability. The overall growth and income profile presents a classic growth-at-any-cost narrative, where significant revenue acceleration is prioritized over immediate income generation or shareholder returns, creating a high-risk, high-reward dynamic dependent on future operational efficiencies.